| miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ... Journal of cellular physiology 228 (7), 1506-1515, 2013 | 198 | 2013 |
| Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials D Ciliberto, C Botta, P Correale, M Rossi, M Caraglia, P Tassone, ... European Journal of Cancer, 2012 | 169 | 2012 |
| miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies N Amodio, M Rossi, L Raimondi, MR Pitari, C Botta, P Tagliaferri, ... Oncotarget 6 (15), 12837, 2015 | 126 | 2015 |
| Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo E Morelli, E Leone, ME Cantafio, MT Di Martino, N Amodio, L Biamonte, ... Leukemia 29 (11), 2173-2183, 2015 | 120 | 2015 |
| A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells A Gulla, MT Di Martino, ME Gallo Cantafio, E Morelli, N Amodio, C Botta, ... Clinical cancer research 22 (5), 1222-1233, 2016 | 112 | 2016 |
| Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts MR Pitari, M Rossi, N Amodio, C Botta, E Morelli, C Federico, A Gullà, ... Oncotarget 6 (29), 27343, 2015 | 111 | 2015 |
| Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients C Botta, V Barbieri, D Ciliberto, A Rossi, D Rocco, R Addeo, N Staropoli, ... Cancer biology & therapy 14 (6), 469-475, 2013 | 108 | 2013 |
| A p53‐dependent tumor suppressor network is induced by selective miR‐125a‐5p inhibition in multiple myeloma cells M Leotta, L Biamonte, L Raimondi, D Ronchetti, MT Di Martino, C Botta, ... Journal of cellular physiology 229 (12), 2106-2116, 2014 | 107 | 2014 |
| Cetuximab±chemotherapy enhances dendritic cell‐mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen‐specific cytotoxic T‐cell … P Correale, C Botta, MG Cusi, MT Del Vecchio, MM De Santi, ... International journal of cancer 130 (7), 1577-1589, 2012 | 94 | 2012 |
| Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma P Correale, MS Rotundo, C Botta, MT Del Vecchio, C Ginanneschi, ... Clinical cancer research 18 (3), 850-857, 2012 | 94 | 2012 |
| Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma C Perez, C Botta, A Zabaleta, N Puig, MT Cedena, I Goicoechea, ... Blood, The Journal of the American Society of Hematology 136 (2), 199-209, 2020 | 90 | 2020 |
| Bortezomib induces anti–multiple myeloma immune response mediated by cGAS/STING pathway activation A Gulla, E Morelli, MK Samur, C Botta, T Hideshima, G Bianchi, M Fulciniti, ... Blood cancer discovery 2 (5), 468-483, 2021 | 80 | 2021 |
| Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities C Botta, A Gullà, P Correale, P Tagliaferri, P Tassone Frontiers in oncology 4, 348, 2014 | 79 | 2014 |
| Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse V Nardone, C Botta, M Caraglia, EC Martino, MR Ambrosio, T Carfagno, ... Cancer biology & therapy 17 (11), 1213-1220, 2016 | 76 | 2016 |
| Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients EC Martino, G Misso, P Pastina, S Costantini, F Vanni, C Gandolfo, ... Cell death discovery 2 (1), 1-8, 2016 | 76 | 2016 |
| Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis M Arbitrio, MT Di Martino, V Barbieri, G Agapito, PH Guzzi, C Botta, ... Cancer chemotherapy and pharmacology 77, 205-209, 2016 | 73 | 2016 |
| Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients C Botta, D Ciliberto, M Rossi, N Staropoli, M Cuce, T Galeano, ... Blood advances 1 (7), 455-466, 2017 | 66 | 2017 |
| Iron metabolism in the tumor microenvironment—Implications for anti-cancer immune response A Sacco, AM Battaglia, C Botta, I Aversa, S Mancuso, F Costanzo, ... Cells 10 (2), 303, 2021 | 64 | 2021 |
| Radiomics predicts survival of patients with advanced non‑small cell lung cancer undergoing PD‑1 blockade using Nivolumab V Nardone, P Tini, P Pastina, C Botta, A Reginelli, SF Carbone, ... Oncology Letters 19 (2), 1559-1566, 2020 | 64 | 2020 |
| Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials N Staropoli, D Ciliberto, C Botta, L Fiorillo, A Grimaldi, S Lama, ... Cancer biology & therapy 15 (6), 707-720, 2014 | 61 | 2014 |
Pierosandro Tagliaferriprofessore di oncologia medica Università magna graecia di CatanzaroEmail verificata su unicz.it
